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A B S T R A C T
Background
Human albumin solutions are used for a range of medical and surgical problems. Licensed indications are the emergency treatment
of shock and other conditions where restoration of blood volume is urgent, such as in burns and hypoproteinaemia. Human albumin
solutions are more expensive than other colloids and crystalloids.
Objectives
To quantify the effect on mortality of human albumin and plasma protein fraction (PPF) administration in themanagement of critically
ill patients.
Search methods
We searched the Cochrane Injuries Group Specialised Register (searched 31 May 2011), the Cochrane Central Register of Controlled
Trials (CENTRAL) (The Cochrane Library 2011, Issue 2), MEDLINE (Ovid) (1948 to week 3 May 2011), EMBASE (Ovid) (1980 to
Week 21 2011), CINAHL (EBSCO) (1982 to May 2011), ISI Web of Science: Science Citation Index Expanded (SCI-EXPANDED)
(1970 to May 2011), ISI Web of Science: Conference Proceedings Citation Index - Science (CPCI-S) (1990 to May 2011), PubMed
(www.ncbi.nlm.nih.gov/sites/entrez/) (searched 10 June 2011, limit: last 60 days). Reference lists of trials and review articles were
checked, and authors of identified trials were contacted.
Selection criteria
Randomised controlled trials comparing albumin or PPF with no albumin or PPF or with a crystalloid solution in critically ill patients
with hypovolaemia, burns or hypoalbuminaemia.
Data collection and analysis
We collected data on the participants, albumin solution used, mortality at the end of follow up, and quality of allocation concealment.
Analysis was stratified according to patient type.
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Main results
We found 38 trials meeting the inclusion criteria and reporting death as an outcome. There were 1,958 deaths among 10,842 trial
participants.
For hypovolaemia, the relative risk of death following albumin administration was 1.02 (95% confidence interval (CI) 0.92 to 1.13).
This estimate was heavily influenced by the results of the SAFE trial, which contributed 75.2% of the information (based on the weights
in the meta-analysis). For burns, the relative risk was 2.93 (95% CI 1.28 to 6.72) and for hypoalbuminaemia the relative risk was 1.26
(95% CI 0.84 to 1.88). There was no substantial heterogeneity between the trials in the various categories (Chi2 = 26.66, df = 31, P =
0.69). The pooled relative risk of death with albumin administration was 1.05 (95% CI 0.95 to 1.16).
Authors’ conclusions
For patients with hypovolaemia, there is no evidence that albumin reduces mortality when compared with cheaper alternatives such as
saline. There is no evidence that albumin reduces mortality in critically ill patients with burns and hypoalbuminaemia. The possibility
that there may be highly selected populations of critically ill patients in which albumin may be indicated remains open to question.
However, in view of the absence of evidence of a mortality benefit from albumin and the increased cost of albumin compared to
alternatives such as saline, it would seem reasonable that albumin should only be used within the context of well concealed and
adequately powered randomised controlled trials.
P L A I N L A N G U A G E S U M M A R Y
What is the effect of giving human albumin compared to saline to replace lost blood in critically ill or injured people
Trauma, burns or surgery can cause people to lose large amounts of blood. Fluid replacement, giving fluids intravenously (into a vein),
is used to help restore blood volume and hopefully reduce the risk of dying. Blood products (including human albumin), non-blood
products or combinations can be used. This review of 38 trials found no evidence that albumin reduces the risk of dying. Albumin is
very expensive, in which case it may be better to use cheaper alternatives such as saline for fluid replacement.
B A C K G R O U N D
In patients with acute and chronic illness, serum albumin concen-
tration is inversely related to mortality risk. A systematic review of
cohort studies meeting specified criteria estimated that, for each
2.5 g/L decrement in serum albumin concentration, the risk of
death increases by between 24% and 56% (Goldwasser 1997).
The association persists after adjusting for other known risk fac-
tors and pre-existing illness, suggesting a direct protective effect
of the albumin molecule (Goldwasser 1997). Largely as a result
of these observations, human albumin solutions are now used in
the management of a diverse range of medical and surgical prob-
lems. Published indications for human albumin solution include
the emergency treatment of shock and other conditions where
restoration of blood volume is urgent, the acute management of
burns, and clinical situations associated with hypoproteinaemia
(ABPI 1998).
In comparison with other colloidal solutions and with crystalloid
solutions, human albumin solutions are expensive (McClelland
1990). Volume for volume human albumin solution is twice as
expensive as hydroxyethyl starch, and over 30 times more expen-
sive than crystalloid solutions such as sodium chloride or Ringer’s
lactate. Because of the high cost and limited availability of hu-
man albumin, it is particularly important that its use should be
restricted to the indications for which it has been shown to be
effective. To assess the effectiveness and safety of human albumin
solutions in the management of critically ill patients, particularly
those with hypovolaemia from injury or surgery, burns and hy-
poproteinaemia, a systematic review of randomised controlled tri-
als was conducted.
O B J E C T I V E S
To quantify the effect on mortality of human albumin adminis-
tration in the management of critically ill patients.
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M E T H O D S
Criteria for considering studies for this review
Types of studies
We sought to identify all randomised controlled trials of human
albumin or plasma protein fraction (PPF) administration (albu-
min or PPF versus no albumin or PPF, or a crystalloid solution).
Types of participants
Critically ill patients with hypovolaemia, burns or hypopro-
teinaemia. Trials involving patients receiving pre-operative volume
loading or haemodilution, and trials of albumin administration
during paracentesis, were excluded.
Types of interventions
Human albumin solution or plasma protein fraction (PPF).
Types of outcome measures
The principal outcome measure was mortality from all causes as-
sessed at the end of the follow-up period scheduled for each trial.
Search methods for identification of studies
The latest search was carried out in May to June 2011 using the
electronic databases listed below. See Figure 1 for the study iden-
tification and selection process for this update.
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Figure 1. PRISMA diagram: study identification and selection process-latest update only
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Search strategies used for previous versions of this review can be
obtained from the Trials Search Co-ordinator of the Cochrane
Injuries Group.
Electronic searches
We searched the following electronic databases:
• Cochrane Injuries Group Specialised Register (searched
May 31 2011);
• Cochrane Central Register of Controlled Trials (The
Cochrane Library 2011, Issue 2);
• MEDLINE(Ovid) (1948 to week 3 May 2011);
• Embase (Ovid) (1980 to Week 21 2011);
• CINAHL (EBSCO) (1982 to May 2011);
• ISI Web of Science: Science Citation Index Expanded (SCI-
EXPANDED) (1970 to May 2011);
• ISI Web of Science: Conference Proceedings Citation Index
- Science (CPCI-S) (1990 to May 2011);
• PubMed (www.ncbi.nlm.nih.gov/sites/entrez/) (searched 10
June 2011, limit: last 60 days).
Full details of the latest search strategies can be found in Appendix
1.
Searching other resources
For the original searches, trials were identified using BIDS In-
dex to Scientific and Technical Proceedings and by handsearching
29 international journals and the proceedings of several interna-
tional meetings on fluid resuscitation. To identify unpublished tri-
als we searched the register of the Medical Editors’ Trial Amnesty,
and contacted the Medical Directors of Bio Products Laboratory
(Zenalb), Centeon Limited (Albuminar), and Alpha Therapeutic
UK Limited (Albutein).
We have subsequently identified studies by examining reference
lists of included studies and previously published reviews.We have
also contacted authors of included studies to enquire about other
published or unpublished studies that they may be aware of. We
did not limit our searches by date, language or publication status.
Data collection and analysis
One author scanned the titles and abstracts of reports identified
by electronic searching to produce a list of possibly relevant re-
ports. Two authors (PA and IR) then checked the list to determine
which articles to retrieve in full. Disagreements were resolved by
discussion.
The same two authors applied the selection criteria, again resolving
disagreements by discussion. They both extracted data on study
design, allocation concealment, participants, interventions and
mortality. One author (IR) entered the data into Review Manager
and the other (PA) checked it against his data extraction.
Where clarificationon any aspect of a studywas needed, one review
author contacted the author of the trial.
Relative risks and 95%confidence intervals (CI) formortality were
calculated for each trial on an intention-to-treat basis.Heterogene-
ity between trials was tested using a Chi2 test, where P≤ 0.05 was
taken to indicate significant heterogeneity. As long as statistical
heterogeneity did not exist, for dichotomous data summary rela-
tive risks and 95% CIs were calculated using a fixed-effect model.
In the event of statistical heterogeneity, if the source of hetero-
geneity could obviously be related to patient type, or allocation
concealment, we stratified the analyses on that dimension.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
A total of 38 randomised controlled trials were identified that met
the study inclusion criteria. Mortality data were available either
from the published report or on contact with the authors of 38 of
these trials. The five trials for which mortality data could not be
obtained (Ernest 1999; Ernest 2001; McNulty 1993; Oca 1999;
Skillman 1975) included a total of 124 randomised patients, com-
prising 1.14% of the total number of randomised patients in all
trials meeting the study inclusion criteria. One of the trials was an
unpublished trial registered in the Medical Editors’ Trial Amnesty
(Woittiez 1998). Further details about this trial, including data on
mortality, were obtained directly from the trialist. In six trials there
were no deaths in either the intervention or comparison groups.
An intention-to-treat analysis could not be done for nine of 50
patients in one study (Oca 2003) consequently mortality data is
only presented for 41 patients. The trial by Lucas et al was reported
in five publications. An early report gave the mortality data for 52
randomised patients, 27 allocated to receive albumin, 25 allocated
to receive no albumin (Lucas 1978). Subsequent publications in-
dicated that recruitment to the trial continued until 94 patients
were randomised. Mortality data for all the 94 patients were not
published, nor were they available on contact with the author.
Consequently the outcome data for the 52 patients are presented.
For the 32 included trials in which there were one or more deaths
in either the intervention or control groups, allocation conceal-
ment involved a method that would be expected to reduce the risk
of foreknowledge of treatment allocation (pharmacy controlled
randomisation or serially numbered sealed opaque envelopes) in
20 trials, was unclear in eight trials, and inadequate in four trials.
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Risk of bias in included studies
Bland 1973
Randomised control trial. Therapy cards were randomised in pairs
matched for weight. Method of allocation concealment was not
described.
Bland 1976
This study is reported as randomised but the method of allocat-
ing random numbers and method of allocation concealment are
unknown.
Boldt 1993
Randomised controlled trial. Allocation concealment was by the
use of sealed opaque envelopes.
Boutros 1979
The study is reported as randomised but the method of randomi-
sation and allocation concealment are unknown.
Brown 1988
The random sequence was generated using randomnumber tables.
No allocation concealment.
Cooper 2006
Randomisation was accomplished with a computer-generated list
and sequentially numbered sealed, opaque envelopes.
Dubois 2006
Eligible patients were randomised in a 1:1 ratio using sealed en-
velopes.
Ernest 1999
Randomisation was done by the hospital chart number (odd or
even).
Ernest 2001
Randomisation was done by the hospital record number (odd or
even).
Foley 1990
Patients were randomly assigned to either a treatment or non-
treatment group by medical record number.
Gallagher 1985
Randomisation and allocation concealment were by computerised
system.
Golub 1994
Random sequence was computer generated. Allocation conceal-
ment was by the use of sealed opaque envelopes.
Goodwin 1983
Randomisation was according to random number tables. The
methods of allocation concealment were unknown.
Greenhalgh 1995
Randomisation scheme controlled by the pharmacy.
Greenough 1993
Randomised controlled trial. Allocation concealment was by the
use of sealed opaque envelopes.
Grundmann 1982
The study is reported as prospectively randomised, but the meth-
ods of randomisation and allocation concealment are unknown.
Jelenko 1978
The study is reported as randomised but the method of randomi-
sation and allocation concealment are unknown.
Kanarek 1992
Randomised controlled trial. Allocation concealment was by the
use of sealed opaque envelopes.
Lowe 1977
The method of allocating random numbers is unknown. Sealed
envelopes were used to ensure allocation concealment.
Lucas 1978
Allocationwas based on the last digit of each patient’s case number.
Ninety-four patients were randomised in total but the number of
deaths was not reported in the final report. However, in a prelim-
inary report, based on 52 of the randomised patients, deaths were
reported.
Maitland 2005
Randomised control trial using a sealed card system.
Maitland 2011
Multicentre, open, randomised, controlled study. Sealed opaque
envelopes were used to assist allocation concealment.
McNulty 1993
The study is reported as randomised but the method of randomi-
sation and allocation concealment are unknown.
Nielsen 1985
This study is reported as randomised but the method of allocation
concealment is not described.
Nilsson 1980
Randomised controlled trial. Allocation concealment was by the
use of sealed opaque envelopes.
Oca 1999
Randomisation was done by sequentially numbered, sealed,
opaque envelopes.
Oca 2003
Randomisation was accomplished by random number tables via
sealed, serially numbered envelopes.
Pockaj 1994
The study is reported as randomised but the method of randomi-
sation and allocation concealment are unknown.
Prien 1990
The study is reported as randomised but the method of randomi-
sation and allocation concealment are unknown.
Quinlan 2004
Randomised double blind controlled trial.
Rackow 1983
Randomisation was according to a pre-determined randomisation
schedule, but the methods and the allocation concealment are
unknown.
Rubin 1997
Allocation concealment was by a sealed opaque envelope system
in the hospital pharmacy.
SAFE 2004
Central randomisation accessed on the Internet through a secure
website with use of a minimisation algorithm. Blinding was as-
sured through the use of specially designed masking cartons and
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specially designed and manufactured administration sets. The au-
thors report that the effectiveness of the blinding was confirmed
in a formal study before the trial was initiated.
Shah 1977
Randomised controlled trial. Allocation by sealed envelope.
Skillman 1975
The study is reported as randomised but the method of randomi-
sation and allocation concealment are unknown.
So 1997
Randomised controlled trial. Allocation concealment was by com-
puterised system.
Tollofsrud 1995
The method of generating random numbers is unknown. Alloca-
tion concealment was by sealed opaque envelopes.
Virgilio 1979
Randomisation was determined using random number tables.
Methods of allocation concealment are unknown.
Woittiez 1998
Randomised controlled trial. Allocation concealment was by the
use of sealed opaque envelopes.
Wojtysiak 1992
Randomisation was determined using random number tables. Al-
location concealment was inadequate.
Woods 1993
Patients with even hospital numbers were allocated to the group
receiving albumin, while those with odd hospital numbers were
allocated to the group not receiving supplemental albumin.
Zetterstrom 1981a
Patients were randomly divided into two groups. Allocation con-
cealment was by the use of sealed opaque envelopes.
Zetterstrom 1981b
Patients were randomly divided into two groups. Allocation con-
cealment was by the use of sealed opaque envelopes.
Effects of interventions
For hypovolaemia the pooled relative risk of death following albu-
min administration was 1.02 (95% confidence interval (CI) 0.92
to 1.13). This estimate was heavily influenced by the results of
the SAFE trial which received 75.2% of the weight. For burns the
relative risk was 2.93 (95% CI 1.28 to 6.72), and for hypoalbu-
minaemia the relative risk was 1.26 (95% CI 0.84 to 1.88). There
was no substantial heterogeneity between the trials in the various
categories (Chi2 = 26.66, df = 31, P = 0.69). The pooled relative
risk of death with albumin administration was 1.05 (95% CI 0.95
to 1.16).
D I S C U S S I O N
Because many of the trials included in this meta-analysis are small
and many are poorly concealed, the results must be interpreted
with caution. The SAFE trial, however, is a notable exception.
The SAFE trial included a total of 6997 randomised participants,
allocation was well concealed, the use of a minimisation algorithm
helped to ensure that baseline characteristics were well balanced,
vigorous attempts were made to ensure that the participating clin-
icians were blind to the type of fluid that was administered, and an
intention-to-treat analysis was undertaken. The SAFE trial pro-
vided no evidence that albumin reducedmortality in patients with
hypovolaemia, although the possibility of amodest benefit or harm
could not be excluded.
This systematic review was first updated in November 2001. At
that time, one additional trial was identified and included (Bland
1973). This trial compared albumin and dextrose infusions in
new-born infants with low cord serum protein levels who were
considered to be at risk of respiratory distress. This trial meets
the eligibility criteria for the review (hypoproteinaemia) but had
been overlooked in the original search. However, the inclusion of
this trial does not change the conclusions of the review. The latest
update of this review (July 2011) includes one further recently
published trial that meets the inclusion criteria (Maitland 2011);
it does not change the conclusions of the review.
Summary of main results
There is no evidence that albumin reduces mortality in patients
with hypovolaemia, burns or hypoproteinaemia. For patients with
burns or hypoproteinaemia, there is a suggestion that albumin
administration may increase mortality.
Mortality was selected as the outcome measure in this systematic
review for several reasons. In the context of critical illness, death
or survival is a clinically relevant outcome that is of immediate
importance to patients, and data on death are reported in nearly all
studies. Furthermore, one might expect that mortality data would
be less prone tomeasurement error or biased reporting than would
data on pathophysiological outcomes. The use of a pathophysio-
logical end-point as a surrogate for an adverse outcome assumes
a direct relationship between the two, an assumption that may
sometimes be inappropriate. Finally, when trials collect data on a
number of physiological end-points, there is the potential for bias
due to the selective publication of end-points showing striking
treatment effects. Because we obtained mortality data for all but
four of the included trials, the likelihood of bias due to selective
publication of trial outcomes is minimal.
Potential biases in the review process
Although publication bias is a potent threat to the validity of sys-
tematic reviews, it is unlikely to have had an important impact
in this study. There was no evidence of funnel plot asymmetry
on visual inspection. In some of the trials included in this review,
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allocation concealment was inadequate or was unclear. As a re-
sult, it is possible that more severely ill patients were preferentially
allocated to the albumin treated group, which may account for
the increased mortality risk in this group. Nevertheless, when the
analyses were repeated, including only those trials in which allo-
cation concealment involved a method that would be expected to
reduce the risk of foreknowledge of treatment allocation, the point
estimates were little different.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
For patients with hypovolaemia there is no evidence that albumin
reduces mortality when compared with cheaper alternatives such
as saline. There is no evidence that albumin reduces mortality in
critically ill patients with burns and hypoalbuminaemia and there
is a suggestion that albumin may increase the risk of death.
Implications for research
The possibility that there may be highly selected populations of
critically ill patients in which albumin may be indicated remains
open to question. However, in view of the absence of evidence
of a mortality benefit from albumin and the increased cost of
albumin compared to alternatives such as saline, it would seem
reasonable that albumin should only be used within the context
of well concealed and adequately powered randomised controlled
trials.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bland 1973
Methods Randomised controlled trial. Therapy cards were randomised in pairs matched for weight. Method of allocation
concealment not fully described
Participants Newborn infants considered at high risk for developing respiratory distress. Those with a cord serum protein level less
than 4.6g/100ml and at least one of the following; birthweight less than 2500g, gestational age less than 37 weeks,
arterial pH less than 7.25
Interventions 1) Intervention (n=50) received 8ml/kg 25% salt poor albumin.
2) Control group (n=50) received 8ml/kg 5% dextrose in water
Outcomes Deaths reported within 28 days.
Notes
Bland 1976
Methods Randomised controlled trial. Method of allocation concealment not fully described
Participants Premature infants (less than 37 weeks gestation), with hypoproteinaemia (cord serum total protein of 4.6g/100ml or
less)
Interventions 1) Intervention group (n=14) received 8ml/kg salt-poor albumin.
2) Comparison group (n=13) received 8ml/kg glucose in water.
Outcomes Deaths reported.
Notes Length of follow-up unspecified.
Boldt 1993
Methods Randomised controlled trial. Method of allocation concealment not described in published
report. Authors were contacted and confirmed the use of sealed opaque envelopes
Participants Men undergoing elective aortocoronary bypass grafting, who had a pulmonary capillary
wedge pressure of less than 5mmHg after induction of anaesthesia
Interventions 1) Intervention (n=15): Albumin 5%.
2) Control (n=15): No additional volume.
Outcomes Deaths not reported.
Authors were contacted and confirmed that there were no deaths in the albumin nor the
control group
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Boldt 1993 (Continued)
Notes Follow-up to 1 day.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk
Boutros 1979
Methods Randomised controlled trial. Method of allocation concealment not fully described
Participants Participants were undergoing major operative procedures on the abdominal aorta
Interventions 1) Intervention group (n=7) received albumin in 5% dextrose.
2) Control group (n=17) received 5% dextrose in lactated Ringers and 5% dextrose in 0.45 NaCl. Allocated fluids
were used on admission to ICU, following surgery
Outcomes Deaths reported.
Notes Follow-up to 48 hours after the end of the operation.
Brown 1988
Methods Randomised controlled trial. Patients entered into the study were assigned to one of two
treatment groups by a table of random numbers. Method of allocation concealment not
described. Author contacted - no allocation concealment
Participants All patients who required central TPN and had hypoalbuminaemia (serum albumin con-
centration below 3.0g/dl). Patients who were thermally injured, had nephrotic syndrome
or required protein restriction were excluded
Interventions 1) The intervention group received central TPN plus normal serum albumin (n=33).
2) The control group (n=34) received central TPN alone.
Outcomes Deaths reported.
Notes Follow-up to discharge.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) High risk
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Cooper 2006
Methods Randomised controlled trial, not blinded.
Participants Eligible adults over 15 years old suffering from thermal injury not more than 12 hours
before enrolment
Interventions 1) Intervention (n=19) received 5% albumin plus Ringer’s lactate.
2) Control (n=23) received Ringer’s lactate.
Outcomes Multiple Organ Dysfunction Score (MODS) and deaths reported.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk “Patients were allocated to study groups with
stratified randomization with a computer-
generated randomization list and sequentially
numbered sealed, opaque envelopes. Ran-
domization was stratified by center...” p. 81
Dubois 2006
Methods Prospective, controlled, randomized, open, single centre study
Participants All patients admitted to the hospital ICU with serum albumin less than or equal to 30g/
L/. Exclusion criteria were expected length of stay <72 hrs., life expectancy <3 months or
a do not resuscitate order, albumin administration in the preceding 24 hrs. or evidence of
fluid overload
Interventions 1) Intervention (n=50) received 300 mL of 20% albumin solution on day 1 and 200 mL
on subsequent days when serum albumin concentration was lower than 31 g/L.
2) Control (n=50) received Ringer’s Lactate.
Outcomes Effect of albumin on organ function as assessed by a delta Sequential Organ Failure Assess-
ment score. Deaths not reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk “Eligible patients were randomized in a 1:
1 ratio using sealed envelopes. When a pa-
tient was assigned to one group, he or she
remained in that group whether or not he or
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Dubois 2006 (Continued)
she received the planned treatment.”
Ernest 1999
Methods Randomised controlled trial, not blinded.
Participants 18 septic, critically ill patients where a fluid infusion was clinically indicated
Interventions 1) 5% albumin (n=9).
2) normal saline (n=9).
Outcomes Information on death not collected.
Notes Follow up for about an hour after infusion.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) High risk
Ernest 2001
Methods Randomised controlled trial, not blinded.
Participants 40 postoperative cardiac surgical patients.
Interventions 1) 5% albumin (n=23).
2) normal saline (n=17).
Outcomes Information on death not collected.
Notes Follow up for 40 minutes after infusion. Trial conducted in 1992
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) High risk
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Foley 1990
Methods Patients were randomly assigned to either a treatment or non-treatment group by medical
record number
Participants Hypoalbuminaemic (serum albumin <25g/L) critically ill patients. Potential subjects with
Child’s class C cirrhosis were excluded
Interventions 1) The treatment group (n=18) received 25-50g per day of 25% albumin in addition to
full nutritional support with parenteral nutrition. Albumin administration was continued
daily until serum albumin levels exceeded 25 g/L after which patients received additional
albumin as needed to keep the albumin level at 25 g/L or higher.
2) The non treatment group (n=22) received no exogenous concentrated albumin
Outcomes Deaths reported.
Notes Follow up to discharge.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) High risk
Gallagher 1985
Methods Randomised controlled trial. Method of allocation concealment not described. Author
contacted - allocation concealment by computerised system - patient details were entered
before treatment assignment was revealed
Participants Patients after coronary artery bypass graft surgery.
Interventions 1) Treatment group received 5% albumin (n=5).
2) The control group received lactated Ringers (n=5).
Outcomes Deaths were not reported. Author contacted and confirmed that there were no deaths in
either group
Notes Follow-up to 1 day.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk
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Golub 1994
Methods Computer randomisation - method of allocation concealment not described. Author con-
tacted and confirmed that allocation concealment was by the use of sealed opaque envelopes
Participants Patients in the surgical intensive care unit of a community hospital with circulating albumin
concentrations of <3.0g/dL
Interventions 1) The treatment group (n=116) received 37.5g/day of albumin until the circulating albu-
min concentration increased to 3.0g/dL.
2) The control group received no supplemental albumin.
Both groups received standard nutritional support.
Outcomes Deaths reported.
Notes Follow-up to discharge.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk
Goodwin 1983
Methods Randomised controlled trial. Method of allocation concealment not described
Participants 79 thermally injured patients. No other inclusion criteria were reported. All of the participants were previously healthy
young adults
Interventions 1) The treatment group (n=40) group received 2.5% albumin in Ringer’s lactate.
2) The control group (n=39) Ringers lactate. Allocated fluid was used throughout resuscitation
Outcomes Deaths reported.
Notes Follow-up to discharge.
Greenhalgh 1995
Methods Method of random allocation not described. Author contacted and confirmed the use of a
randomisation scheme controlled by the pharmacy
Participants Patients aged 18 years or younger with acute burns.
Interventions 1) High albumin group (n=34): Patients were supplemented with human albumin to
maintain serum levels between 2.5 and 3.5g/dL. Albumin was supplied as a continuous
drip of 25% human albumin at a rate of 3-10mL/hour. Supplementation was discontinued
if serum albumin levels remained >2.5 g/dL without supplementation or if intravenous
support was discontinued.
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Greenhalgh 1995 (Continued)
2) Low albumin group (n=36): Patients were not given albumin supplementation unless
levels dropped <1.5 g/dL. During burn shock, patients were allowed to receive albumin if
they had levels <2.0 g/dL and were receiving >4 mL/Kg/% burn fluid resuscitation
Outcomes Deaths reported.
Notes Follow-up to discharge.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk
Greenough 1993
Methods Randomised controlled trial. Allocation concealment by sealed opaque envelopes
Participants Infants between 24 and 34 weeks gestational age, who were ventilator dependent, and had
a serum albumin level of less than or equal to 30g/l
Interventions 1)Intervention group (n=20) received 5ml/kg 20% salt-poor human albumin.
2) Control group (n=20) received 5ml/kg of the infant’s maintenance fluids
Outcomes Deaths were not reported. Author contacted and provided data on deaths
Notes Follow-up to 24 hours after infusion.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk
Grundmann 1982
Methods Randomised controlled trial. Method of allocation concealment not fully described
Participants Participants were undergoing partial gastrectomy. The average age was 50 years (range 19-84)
Interventions 1) Intervention group (n=14) group received human albumin.
2) Control group (n=6) details of crystalloid were not reported.
Allocated fluid was continued for 4 days after operation.
Outcomes Deaths reported.
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Grundmann 1982 (Continued)
Notes Follow-up to discharge.
Jelenko 1978
Methods Randomised controlled trial. Method of allocation concealment not described
Participants Participants had burns covering more than 20% of body surface
Interventions 1) Intervention group (n=7) received albumin in hypertonic saline (240MeQ Na+, 120 MeQ Chloride, 120 MeQ
lactate, 3.5 torr/liter);
2) Control group (n=7) received hypertonic saline (240MeQ Na+, 120 MeQ Chloride, 120 MeQ lactate). Allocated
fluid was used to the end of resuscitation
Outcomes Deaths reported.
Notes Follow-up to 5 days.
Kanarek 1992
Methods Randomised controlled trial. Allocation concealment by sealed opaque envelopes
Participants Sick premature newborn infants whose serum albumin was less than 3g/dL
Interventions 1) Intervention group (n=12) received TPN with added albumin.
2) Control group (n=12) received no added albumin.
Outcomes Deaths reported.
Notes Length of follow-up unspecified.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk
Lowe 1977
Methods Randomised controlled trial. The solutions were randomised by opening a sealed envelope
containing a card denoting the appropriate fluid
Participants Participants were undergoing emergency laparotomy for acute abdominal trauma
Interventions 1) Intervention group (n=57) received 50g albumin in 200ml in Ringers lactate;
2) Crystalloid group (n=84) received Ringer’s lactate. Allocated fluid was used throughout
the pre- and intra-operative period
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Lowe 1977 (Continued)
Outcomes Deaths reported.
Notes Follow-up to 5 days post-operatively. Data on the 30 participants with chest injuries who
were left out of the Lowe 1977 report, but included in Moss 1981, have been included in
the meta-analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk
Lucas 1978
Methods Randomised controlled trial. Randomisation was based on the last digit of each patient’s
case number
Participants 52 seriously injured patients.
Interventions 1) Intervention group (n=27) received supplemental salt-poor albumin totaling amaximum
of 150g during operation and 150g per day over the next five days.
2) Control group (n=25) received standard resuscitation regimen but no supplemental
albumin
Outcomes Deaths reported.
Notes In the final report of 94 randomised patients deaths were not reported. However, in this
preliminary report of 52 injured patients deaths were reported
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) High risk
Maitland 2005
Methods Unblinded, randomised, controlled trial.
Participants Kenyan children older than 2 months with symptomatic sever malarial anaemia (haemo-
globin less than 5g/dl)
Interventions 1) Intervention (n=23) received 4.5% albumin.
2) Intervention (n=20) received 0.9% saline.
3) Control (n=18) received only maintenance (rescue emergency intervention when re-
quired)
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Maitland 2005 (Continued)
Outcomes Change in perfusion rates. Deaths not reported.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk “On admission to the HDU, children were
randomly assigned to PTM with one of the
three treatments using sealed card system. The
sealed cards were available 24h/day; either the
admitting doctor or nurse assigned the therapy
at admission based on laboratory results or, in
an emergency, on clinical suspicion.” p. 128
Maitland 2011
Methods Multicentre open, randomised, controlled study
Participants Children (n=3170) aged between 60 days and twelve years of age, with severe febrile illness,
randomly assigned within two strata (stratum A was children with severe febrile illness and
impaired perfusion but without severe hypotension - stratum B was children with severe
hypotension)
Interventions Children were randomly allocated to rapid volume replacement over the course of 1 hour
with either:
1) 20 ml 5% Human Albumin solution per kg body weight (n=1063)
2) 20 ml 0.9% Saline solution per kg body weight (n=1063)
Outcomes Mortality at 4 weeks after randomisation
Notes Children (n=1044) assigned to no treatment were not included in the analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk Trial numbers kept inside opaque, sealed en-
velopes. Opened in numerical order by clin-
ician
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McNulty 1993
Methods Randomised controlled trial. Method of allocation concealment not described
Participants 28 Patients following elective cardiopulmonary bypass.
Interventions 1) Intervention group (n=14) received 5% albumin.
2) Control group (n=14) received isotonic crystalloid.
Outcomes Deaths not reported.
Notes Length of follow-up unspecified.
Myburgh 2007
Methods A double blind, randomised, controlled SAFE 2004 trial. “Randomization was stratified by
a diagnosis of trauma (defined as injury to the body caused by mechanical forces, excluding
burns).” p. 875
Participants 460 patients with traumatic brain injuries.
Interventions 1) Intervention (n=231) received 4% albumin.
2) Control (n=229) received normal saline.
Outcomes Mortality rate at 28 days.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk “Randomization was carried out centrally
with the use of a minimization algorithm,
and the service was accessed on the Internet
through a secure Web site.” SAFE 2004 p.
2248
Nielsen 1985
Methods Randomised controlled trial. Method of allocation concealment not described
Participants Patients admitted for reconstructive surgery of the abdominal aorta. Twenty six patients were randomised
Interventions 1) Intervention (n=13): 80 g of albumin administered in units of 100 ml 20% human serum albumin on the day of
the operation and 20 g albumin daily on the following three postoperative days.
2) Control group (n=13): no supplemental albumin.
Outcomes Deaths not reported. Author when contacted confirmed that there were no deaths in either group
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Nielsen 1985 (Continued)
Notes Follow-up 4 days.
Nilsson 1980
Methods Randomised controlled trial. Allocation concealment by sealed opaque envelopes
Participants Patients with colorectal cancer undergoing elective surgery with resection of the tumour
and primary anastomosis
Interventions 1) Intervention group (n=29) received 20-25g per day of albumin (as 5% albumin or 20%
albumin) for three days, starting on the day after the operation.
2) Control group (n=30) received no albumin.
Outcomes Deaths reported.
Notes Follow up to discharge.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk
Oca 1999
Methods Randomised controlled trial. Allocation concealment was by the use of sealed opaque
sequentially numbered envelopes. Information obtained on contact with the author
Participants 24 neonates being treated for hypotension. Hypotension was defined as an oscilometric
mean arterial blood pressure <30 mmHg for at least 30 minutes. Exclusion criteria con-
sisted of proven sepsis, life-threatening congenital abnormalities, congenital hear disease,
unresolved thoracic air leak, insulin-requiring maternal diabetes mellitus or treatment with
high-frequency ventilation
Interventions 1) 5% albumin (n=11).
2) normal saline (n=13).
Outcomes Mean arterial blood pressure.
Notes Follow-up to discharge.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk
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Oca 2003
Methods Randomised, unblinded, controlled trial.
Participants Newborn infants who were <24 hours old and were admitted to the ICU to receive one of
two solutions for volume expansion. 41 infants were included in the trial
Interventions 1) Intervention (n=21) received 4% albumin.
2) Control (n=20) received normal saline.
Outcomes Magnitude of change in mean arterial blood pressure.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk “Randomizationwas accomplished by random
number tables via sealed, serially numbered en-
velopes” p. 474
Pockaj 1994
Methods Randomised controlled trial. Method of allocation concealment not described
Participants Participants required fluid resuscitation as a result of vascular leak syndrome associated with Interleukin-2 therapy
for metastatic cancer
Interventions 1) Intervention group (n=54) received 5% albumin n 154meq/L NaCl;
2) Control group (n=53) received 0.9% normal saline with 154Meq/L NaCl
Outcomes Deaths reported.
Notes Length of follow-up unspecified.
Prien 1990
Methods Randomised controlled trial. Method of allocation concealment not described
Participants Patients undergoing hemipancreato-duodenectomy (Whipple’s operation)
Interventions 1) Intervention group (n=6) received 20% human albumin to maintain central venous pressure at the pre-operative
level.
2) Control group (n=6) received Ringer’s lactate.
Outcomes Deaths reported.
Notes Length of follow-up unspecified.
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Quinlan 2004
Methods Prospective, randomised, placebo-controlled study.
Participants Patients meeting the American European Consensus criteria for acute lung injury
Interventions 1) Intervention (n=10) received albumin (25g of a 25% solution) every 8 hrs for a total of
nine doses.
2) Control (n=10) received normal saline administered in identical fashion and volume
Outcomes Deaths noted.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk “Patients were randomized to receive 25g of
human albumin every 8 hrs or a placebo
(normal saline, administered in a double-
blind fashion and targeted to normalization
of serum total protein.” p. 755 - 756
Rackow 1983
Methods Randomised controlled trial. Method of allocation concealment not described
Participants Participants were above 18 years of age, and had any one of the following pre-determined indicators of shock: systolic
blood pressure of 90mmHg or less, a cardiac index of less than 2.2L./min.m2, a serum arterial lactate greater than
18mg/dl and WP less than 15mmHg
Interventions 1) Intervention group ( n= 9) received 5% albumin.
2) Control group (n=8) received 0.9% NaCl. Allocated fluid was given as needed until the end of resuscitation
Outcomes Deaths reported.
Notes Follow-up to discharge.
Rubin 1997
Methods Patients were randomised using “a closed envelope system in the pharmacy”
Participants Patients with hypoalbuminaemia (<2.5g/dL) who required TPN for at least six days, were
not pregnant or under age, and did not have metastatic cancer, cirrhosis, or nephrotic
syndrome
Interventions 1) Intervention group (n=16) 25g on normal serum albumin.
2) Control group (n=15) 100 mL of normal saline placebo over a 1 hour period daily
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Rubin 1997 (Continued)
Outcomes Deaths reported.
Notes Follow-up to discharge.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk
SAFE 2004
Methods Central randomisation accessed on the Internet through a secure website with use of a
minimisation algorithm.Blindingwas assured through the use of specially designedmasking
cartons and specially designed and manufactured administration sets. The authors report
that the effectiveness of the blinding was confirmed in a formal study before the trial was
initiated
Participants Patients 18 years of age or older admitted to ICU who the treating clinician judged to
require fluid administration tomaintain or increase intravascular volume, with this decision
supported by the fulfilment of at least one objective criterion. Patients admitted after cardiac
surgery, after liver transplantation, or for the treatment of burns were excluded
Interventions 1) 4% Albumin or
2) Normal saline
The allocated study treatment was used for all fluid resuscitation in the ICU until death
or discharge or until 28 days after randomisation. The treating clinicians determined the
amount and rate of fluid administration according to each patient’s clinical status and
response to treatment
Outcomes Deaths reported.
Notes 28 day mortality.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk “Randomization was carried out centrally
with the use of a minimization algorithm
and the service was accessed on the Internet
through a secure Web site.” p. 2248
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Shah 1977
Methods Randomised controlled trial, allocation by sealed envelope.
Participants Patients with severe, multiple trauma and a systolic blood pressure of less than 90mmHg.
All patients were adults and both sexes were included
Interventions 1) Intervention group (n=9) 5% salt-poor albumin in Ringers lactate.
2) Control group (n=11) Ringer’s lactate for resuscitation, volume infused guided by phys-
iological parameters
Outcomes Death reported.
Notes Length of follow-up not stated.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk
Skillman 1975
Methods Randomised controlled trial. Method of allocation concealment not described
Participants Participants were undergoing elective abdominal reconstructive surgery
Interventions 1) Intervention group received 25% concentrated salt-poor albumin and 5% albumin in saline.
2) Control group received Ringer’s lactate with 5% dextrose. Allocated fluid was given intra-operatively. All patients
received crystalloids only for pre-loading before surgery
Outcomes Deaths were not reported. Author could not be contacted.
Notes Follow-up to 1 day.
So 1997
Methods Randomised controlled trial. Method of allocation concealment not described. Author
contacted and confirmed that allocation concealment was by computer randomisation.
Details of patient were entered before group allocation revealed
Participants Pre-term infants weighing 540 to 1959g at birth, with gestational ages of 23 to 34 weeks,
who developed hypotension within the first two hours of life
Interventions 1) Intervention group (n=32) were given 5% albumin at a dose of 10mg/Kg by slow
intravenous infusion over 30 minutes.
2) Control group (n=31) were given 0.9%NaCl at a dose of 10mg/kg by slow intravenous
infusion over 30 minutes
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So 1997 (Continued)
Outcomes Deaths reported.
Notes Follow up to discharge.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk
Tollofsrud 1995
Methods Randomised controlled trial. Allocation concealment by sealed opaque envelopes
Participants Patients undergoing elective coronary artery bypass surgery. Patients with left ventricular
ejection fraction less than 40%, valvular heart disease, ventricular aneurysm, arrhythmia,
diabetes mellitus, renal failure or lung disease were excluded
Interventions 1) Intervention group (n=10) received albumin 40mg/ml whenever fluid was required to
stabilise haemodynamics.
2) Control group (n=10) received Ringers acetate.
Outcomes Deaths reported.
Notes Follow-up to 48 hours.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk
Virgilio 1979
Methods Randomised controlled trial. Method of allocation concealment not described
Participants Participants were undergoing abdominal aortic surgery.
Interventions 1) Intervention group (n=15) received 5% albumin in Ringer’s lactate
2) Control group (n=14) received Ringers lactate. Allocated fluid was used during operation for maintenance of pre-
defined physiological parameters, and the resuscitation was continued with the allocated fluid until the day following
the operation. This was followed by 5% dextrose in half-normal saline, with potassium chloride as needed
Outcomes Deaths reported.
29Human albumin solution for resuscitation and volume expansion in critically ill patients (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Virgilio 1979 (Continued)
Notes Follow-up 2 and a half weeks.
Woittiez 1998
Methods Randomised controlled trial. Allocation concealment by sealed opaque envelopes
Participants Post-operative intensive care patients.
Interventions 1) Intervention group (n=15) received 20% albumin.
2) Control group (n=16) received 0.9% NaCl.
Outcomes Unpublished data on deaths were provided by the trialist.
Notes Length of follow-up unspecified.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk
Wojtysiak 1992
Methods Randomised controlled trial. Table of random numbers was used to generate the random
sequence. Method of allocation concealment not described in published report. The author
was contacted and indicated that there was inadequate allocation concealment
Participants Patients between the ages of 18 and 75 years who were to receive parenteral nutrition and
had a serum albumin concentration <3.0 g/dL. Patients were excluded if they had renal
impairment, liver impairment or were haemodynamically unstable
Interventions 1) Intervention group (n= 15) had 25g of human albumin added to each litre of parenteral
nutrition.
2) Control group (n=15) had no supplemental albumin.
Outcomes Deaths not reported in published report. Author when contacted confirmed that there were
no deaths in either group
Notes Follow-up to 5 days.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) High risk
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Woods 1993
Methods Randomised controlled trial. Patients with even hospital numbers were randomised to the
group receiving albumin while those patients with odd hospital numbers were randomised
to the group not receiving supplemental albumin
Participants Patients undergoing surgery for abdominal aortic aneurysm, aortoiliac or aortofemoral
bypass
Interventions 1) Intervention group (n=37): albumin was replaced to a level greater than or equal to 3.5
g/dL.
2) Control group (n=32): received no supplemental albumin.
Outcomes Deaths reported.
Notes Follow-up to discharge.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) High risk
Zetterstrom 1981a
Methods The patients were randomly divided into two groups. The method of allocation conceal-
ment is not described. Author was contacted and confirmed the use of sealed opaque en-
velopes
Participants Adult patients undergoing elective major abdominal surgery.
Interventions 1) Intervention group (n=15)
2) Control group (n=15)
A similar schedule of fluid therapy and blood replacement was followed in the interven-
tion and control groups. However, the albumin group received a 20% solution of human
albumin intravenously according to the following scheme:
At the end of the operation: 100ml.
Postoperatively on the day of the operation: 200-300 ml.
First day after the operation: 200 ml.
Following 3 days 100 ml each day.
Outcomes Deaths reported.
Notes Length of follow-up unspecified.
Risk of bias
Bias Authors’ judgement Support for judgement
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Zetterstrom 1981a (Continued)
Allocation concealment (selection bias) Low risk
Zetterstrom 1981b
Methods Patients were randomly divided into two groups. Method of allocation concealment was
not described. Author was contacted and confirmed the use of sealed opaque envelopes
Participants Patients undergoing elective reconstruction of the abdominal aorta
Interventions 1) Intervention group (n=9)
2) Control group (n=9)
Postoperatively, the aimof fluid administrationwas to keep the pulmonary arterial occlusion
pressure equal to the preoperative level. When lower values were recorded, the patients in
the control group were given a balanced electrolyte solution of the Ringer type, whereas
the albumin patients received a 5% solution of human albumin
Outcomes Deaths reported.
Notes Length of follow-up unspecified.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Artru 1989 Intervention to control intracranial pressure not directed at fluid resuscitation
Bellomo 2006 Trial was subset of SAFE 2004 trial, thus offering no new data.
Brehme 1993 Intervention directed at haemodilution, not at volume replacement
Carlon 1979 Randomised controlled trial of pre-operative volume expansion during anaesthesia
Fiorica 1991 Not a randomised trial. The first 18 patients received standard maintenance crystalloid solution. The next 10
consecutive patients received 100g of a concentrated 25% albumin solution
Goslinga 1992 Intervention directed at haemodilution, not volume replacement
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(Continued)
Grundmann 1985 This was a randomised controlled trial of 220 patients, 106 were given albumin when their colloid osmotic
pressure (COP) fell below 24 cm water and 114 were given albumin when their COP fell below 29 cm water.
Patients were not randomised to albumin or no albumin, nor were they randomised to supplemental albumin
versus normal amounts of albumin, rather, this was a trial of different criteria for albumin supplementation. It
is unlikely therefore that the two arms of the trial were comparable and hence the trial is excluded
Grundmann 1986 This was a randomised controlled trial to examine whether postoperative human albumin supply is justified in
intensive care patients in the case that the colloid osmotic pressure decreases below 26 centimetres of water. The
therapy group received human albumin only if the colloid osmotic pressure dropped below 26 cm water. The
control group also received albumin but only for resuscitation of cardiac output and central venous pressure.
The trial was excluded because both intervention and control groups received albumin
Hauser 1980 Cross-over trial.
Lagonidis 1995 Intervention was pre-loading for coronary artery bypass surgery
Lennihan 2000 Participants had suffered subarachnoid hemorrhage and therefore did not meet the inclusion criteria
Magder 1999 Participants were stable patients following cardiopulmonary bypass surgery and therefore did not meet the
inclusion criteria
Maitland 2005a Trial was subset of SAFE 2004 trial, thus offering no new data.
Martin 1999 Intervention involved comparison of albuminwith furosemide verus placebo therefore did notmeet the inclusion
criteria
Metildi 1984 Participants were admissions to an intensive care and a trauma unit with adult respiratory distress syndrome
and established pulmonary failure. Included both trauma and non-trauma patients and therefore did not meet
the inclusion criteria for the review
Steinberg 1989 Cross-over trial.
Tomita 1994 Randomised controlled trial of normal versus high oncotic pressure following head injury. Patients were not
randomised to albumin or no albumin. Albumin and furosemide were used together to achieve high oncotic
pressure
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D A T A A N D A N A L Y S E S
Comparison 1. Supplemental albumin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 deaths 38 10842 Odds Ratio (M-H, Fixed, 95% CI) 1.05 [0.95, 1.16]
1.1 hypovolaemia 22 9880 Odds Ratio (M-H, Fixed, 95% CI) 1.02 [0.92, 1.13]
1.2 burns 4 205 Odds Ratio (M-H, Fixed, 95% CI) 2.93 [1.28, 6.72]
1.3 hypoalbuminaemia 12 757 Odds Ratio (M-H, Fixed, 95% CI) 1.26 [0.84, 1.88]
Analysis 1.1. Comparison 1 Supplemental albumin, Outcome 1 deaths.
Review: Human albumin solution for resuscitation and volume expansion in critically ill patients
Comparison: 1 Supplemental albumin
Outcome: 1 deaths
Study or subgroup albumin control Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 hypovolaemia
Boldt 1993 0/15 0/15 0.0 [ 0.0, 0.0 ]
Boutros 1979 0/7 2/17 0.41 [ 0.02, 9.73 ]
Gallagher 1985 0/5 0/5 0.0 [ 0.0, 0.0 ]
Grundmann 1982 1/14 0/6 1.44 [ 0.05, 40.54 ]
Lowe 1977 3/57 3/84 1.50 [ 0.29, 7.71 ]
Lucas 1978 7/27 0/25 18.66 [ 1.01, 346.35 ]
Maitland 2005 4/23 6/38 1.12 [ 0.28, 4.49 ]
Maitland 2011 137/1063 135/1063 1.02 [ 0.79, 1.31 ]
Nielsen 1985 0/13 0/13 0.0 [ 0.0, 0.0 ]
Oca 2003 4/21 1/20 4.47 [ 0.45, 44.01 ]
Pockaj 1994 0/54 0/53 0.0 [ 0.0, 0.0 ]
Prien 1990 0/6 0/6 0.0 [ 0.0, 0.0 ]
Rackow 1983 6/9 6/8 0.67 [ 0.08, 5.54 ]
SAFE 2004 726/3473 729/3460 0.99 [ 0.88, 1.11 ]
0.02 0.1 1 10 50
Favours treatment Favours control
(Continued . . . )
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(. . . Continued)
Study or subgroup albumin control Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Shah 1977 2/9 3/11 0.76 [ 0.10, 5.96 ]
So 1997 7/32 5/31 1.46 [ 0.41, 5.20 ]
Tollofsrud 1995 0/10 1/10 0.30 [ 0.01, 8.33 ]
Virgilio 1979 1/15 1/14 0.93 [ 0.05, 16.42 ]
Woittiez 1998 8/15 4/16 3.43 [ 0.75, 15.67 ]
Woods 1993 1/37 0/32 2.67 [ 0.11, 67.89 ]
Zetterstrom 1981a 0/15 1/15 0.31 [ 0.01, 8.28 ]
Zetterstrom 1981b 2/9 0/9 6.33 [ 0.26, 152.86 ]
Subtotal (95% CI) 4929 4951 1.02 [ 0.92, 1.13 ]
Total events: 909 (albumin), 897 (control)
Heterogeneity: Chi2 = 11.84, df = 16 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.33 (P = 0.74)
2 burns
Cooper 2006 3/19 1/23 4.13 [ 0.39, 43.38 ]
Goodwin 1983 11/40 3/39 4.55 [ 1.16, 17.86 ]
Greenhalgh 1995 7/34 3/36 2.85 [ 0.67, 12.10 ]
Jelenko 1978 1/7 2/7 0.42 [ 0.03, 6.06 ]
Subtotal (95% CI) 100 105 2.93 [ 1.28, 6.72 ]
Total events: 22 (albumin), 9 (control)
Heterogeneity: Chi2 = 2.52, df = 3 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 2.53 (P = 0.011)
3 hypoalbuminaemia
Bland 1973 9/50 12/50 0.70 [ 0.26, 1.83 ]
Bland 1976 4/14 1/13 4.80 [ 0.46, 50.16 ]
Brown 1988 6/34 4/33 1.55 [ 0.40, 6.10 ]
Dubois 2006 12/50 15/50 0.74 [ 0.30, 1.79 ]
Foley 1990 7/18 6/22 1.70 [ 0.45, 6.44 ]
Golub 1994 12/116 6/103 1.87 [ 0.67, 5.16 ]
Greenough 1993 6/20 4/20 1.71 [ 0.40, 7.34 ]
Kanarek 1992 3/12 2/12 1.67 [ 0.22, 12.35 ]
Nilsson 1980 1/29 0/30 3.21 [ 0.13, 82.07 ]
Quinlan 2004 4/10 4/10 1.00 [ 0.17, 5.98 ]
Rubin 1997 2/16 1/15 2.00 [ 0.16, 24.66 ]
Wojtysiak 1992 0/15 0/15 0.0 [ 0.0, 0.0 ]
0.02 0.1 1 10 50
Favours treatment Favours control
(Continued . . . )
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Study or subgroup albumin control Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 384 373 1.26 [ 0.84, 1.88 ]
Total events: 66 (albumin), 55 (control)
Heterogeneity: Chi2 = 5.71, df = 10 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 1.11 (P = 0.27)
Total (95% CI) 5413 5429 1.05 [ 0.95, 1.16 ]
Total events: 997 (albumin), 961 (control)
Heterogeneity: Chi2 = 26.66, df = 31 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Chi2 = 6.96, df = 2 (P = 0.03), I2 =71%
0.02 0.1 1 10 50
Favours treatment Favours control
A P P E N D I C E S
Appendix 1. Search strategy
PubMed [www.ncbi.nlm.nih.gov/sites/entrez/] (searched 10 June 2011 limit: last 60 days)
Cochrane Injuries Group Specialised Register (searched 31 May 2011)
1.fluid* and (solution* or replac* or therap* or substitut* or restorat* or resuscitat* or rehydrat*)
2.rehydrate* and (solution* or replac* or therap* or substitut* or restorat* or resuscitat* or rehydrat*)
3.volum* and (solution* or replac* or therap* or substitut* or restorat* or resuscitat* or rehydrat*)
4.1 or 2 or 3
5.Albumin*
6.4 and 5
Cochrane Central Register of Controlled Trials 2011, Issue 2 (The Cochrane Library)
#1MeSH descriptor Fluid Therapy explode all trees
#2fluid*
#3((volume or rehydrat*) near3 (solution* or replac* or therap* or substitut* or restorat* or resuscitat* or rehydrat*))
#4(#1 OR #2 OR #3)
#5MeSH descriptor Albumins explode all trees
#6MeSH descriptor Serum Albumin explode all trees
#7albumin*
#8(#5 OR #6 OR #7)
#9(#4 AND #8)
#10(#9), from 2008 to 2011
MEDLINE (Ovid) 1948 to Week 3 May 2011
1.exp Fluid Therapy/
2.fluid*.ti,ab.
3.((volume or rehydrat*) adj3 (solution* or replac* or therap* or substitut* or restorat* or resuscitat* or rehydrat*)).ti,ab.
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4.1 or 2 or 3
5.exp Albumins/
6.exp Serum Albumin/
7.albumin*.mp.
8.5 or 6 or 7
9.4 and 8
10.randomi?ed.ab,ti.
11.randomized controlled trial.pt.
12.controlled clinical trial.pt.
13.placebo.ab.
14.clinical trials as topic.sh.
15.randomly.ab.
16.trial.ti.
17.10 or 11 or 12 or 13 or 14 or 15 or 16
18.(animals not (humans and animals)).sh.
19.17 not 18
20.9 and 19
21.(2008* or 2009* or 2010* or 2011*).ed.
22.20 and 21
EMBASE (Ovid) 1980 to Week 21 2011
1.albumin*.ab,ti.
2.exp human serum albumin/
3.exp recombinant human serum albumin/
4.exp serum albumin/
5.1 or 2 or 3 or 4
6.exp fluid resuscitation/
7.((volume or rehydrat*) adj3 (solution* or replac* or therap* or substitut* or restorat* or resuscitat* or rehydrat*)).ti,ab.
8.fluid*.ti,ab.
9.6 or 7 or 8
10.5 and 9
11.exp Randomized Controlled Trial/
12.exp controlled clinical trial/
13.randomi?ed.ab,ti.
14.placebo.ab.
15.*Clinical Trial/
16.randomly.ab.
17.trial.ti.
18.11 or 12 or 13 or 14 or 15 or 16 or 17
19.exp animal/ not (exp human/ and exp animal/)
20.18 not 19
21.10 and 20
22.(2008* or 2009* or 2010* or 2011*).em.
23.21 and 22
CINAHL (EBSCO) 1982 to May 2011
S1(MH “Fluid Therapy+”)
S2Fluid*
S3(volume or rehydrat*) and (solution* or replac* or therap* or substitut* or restorat* or resuscitat* or rehydrat*)
S4S1 or S2 or S3
S5albumin*
S6(MH “Albumins+”)
S7(MH “Serum Albumin”)
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S8S5 or S6 or S7
S9(MH “Clinical Trials+”)
S10 (MH “Randomized Controlled Trials”)
S11 S9 or S10
S12 S4 and S8 and S12
S13 S12 (2008-11)
ISI Web of Science: Science Citation Index Expanded (SCI-EXPANDED) 1970 to May 2011, ISI Web of Science: Conference
Proceedings Citation Index- Science (CPCI-S) 1990 to May 2011
1.Topic=((volume or rehydrat*) same (solution* or replac* or therap* or substitut* or restorat* or resuscitat* or rehydrat*)) OR Topic=
(Fluid*)
2.Topic=(albumin*)
3.1 and 2
4.Topic=((singl* OR doubl* OR trebl* OR tripl*) SAME (blind* OR mask*))
5.Topic=(randomised OR randomized OR randomly OR random order OR random sequence OR random allocation OR randomly
allocated OR at random OR randomized controlled trial) OR Topic=(controlled clinical trial OR controlled trial OR clinical trial OR
placebo)
6.4 or 5
7.Topic=(human*)
8.6 and 7
9.3 and 8
F E E D B A C K
Human albumin solution
Summary
1. It would be helpful to state that this review was published in the BMJ in 1998, to summarise the subsequent correspondence in
print and on the BMJ website, and to note the respects (if any) in which this Cochrane review differs from the BMJ publication.
2. It would be valuable to summarise the report of the Committee for Safety of Medicines (CSM) on this review in the Comments and
Criticisms section, with a rejoinder by the authors.
3. Because mortality was not the primary endpoint in any of the trials reviewed, it would be useful to note the primary outcomes of
each trial, under ’characteristics of included trials’.
4. It would be helpful if the number of participants in each arm of each
reviewed trial appeared under ’characteristics of included trials.’
Reply
1. We agree that it is important to direct the reader to other published versions of the review and will ensure that readers are alerted to
the BMJ publication. We do not think it is appropriate to summarise the correspondence in response to this review, as to do so would
run the risk of misrepresenting the views of the correspondents. At the time of first publication the Cochrane review was identical to
the review published in the BMJ. However, the Cochrane review will be regularly updated to take account of new information from
randomised controlled trials.
2. TheCochraneDatabase of Systematic Reviews is an international database and for this reasonwe believe that it would be inappropriate
to give undue emphasis to the deliberations of the British Committee on Safety of Medicines (CSM).
3. Mortality was recorded in all but two of the trials included in our systematic review. However, we have no information on whether
this was considered by the trialist to be the primary endpoint and would be interested to hear where the author of the comment found
this information. How does the author of the comment define a primary endpoint? The concept of a primary endpoint implies a
selection within the mind of the trialist of the most important endpoint. We would also ask whether it is appropriate that a process
38Human albumin solution for resuscitation and volume expansion in critically ill patients (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
within the mind of a trialist should impact importantly on the estimation of the effect of albumin on mortality, and if so, what is the
scientific basis for this.
4. We have included the number of participants in each arm of each reviewed trial in the section ’characteristics of included trials’ as
suggested.
Contributors
Author of comments: Dr Andrew Herxheimer
Author of Responses: Ian Roberts
Human albumin solution
Summary
I gather that a further trial - prompted by the review - is now planned and possibly underway in Australasia. If so, I think this should
be mentioned, preferably with a link to a record for the trial on the meta-Register of Controlled Trials.
Reply
Details of this ongoing trial are now in the on-going studies section.
Contributors
Author of comments: Ian Chalmers, UK
Author of response: Ian Roberts, UK
Human albumin solution
Summary
Human albumin solution for resuscitation and volume expansion in critically ill patients
Summary of comment
1. In the hypovolaemia group, five randomised controlled trials were incorrectly included and should be deleted(1).
2. The Cochrane Albumin Review excluded or omitted extensive randomised controlled trials’ evidence in the three categories of
indications, namely, hypovolaemia, burns and hypoalbuminaemia(2) and this excluded and omitted evidence indicated that albumin
may reduce rather than increase mortality.
(1) Horsey P Albumin and hypovolaemia - is the Cochrane evidence to be trusted? Lancet 2002 359 70-72
(2) Willkes MM and Navickis RJ Patient survival after human albumin administration: a meta-analysis of randomised controlled trials.
Annals of Internal Medicine 2001 135 149-164
I certify that I have no affiliations with or involvement in any organisation or entity with a direct financial interest in the subject matter
of my criticisms.
Reply
We are grateful to Dr Horsey for his thoughtful comments on our systematic review of albumin administration in critically ill patients.
The comments were first made as a commentary in The Lancet (2002;359:70-72). Our response to these comments was published in
the same issue (Lancet 2002:359:72-3). We are pleased that this discussion will now be available to readers of the Cochrane Library.
Dr Horsey feels that some of the trials included under the category ’hypovolaemia’ would be more appropriate in a different category.
We accept that in some clinical situations hypovolaemia and hypoalbuminaemia co-exist so that deciding which category would be
most appropriate is a matter for judgement. Also, as Dr Horesy points out, the relationship between hypovolaemia and low blood
39Human albumin solution for resuscitation and volume expansion in critically ill patients (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
pressure can be complicated, and the presence of the latter might not always signify the former. Nevertheless, our judgements about
the categories were made without knowledge of the results of the trials and we are reluctant to change these post-hoc.
We are grateful to Dr Horsey for drawing our attention to the meta-analysis by Wilkes et al that was funded by the Plasma Protein
Therapeutics Association. Because the inclusion criteria for the Cochrane Injuries Group Albumin Reviewer and the Wilkes reviews
are different it does not follow that the two reviews should include the same trials.
We are pleased that our systematic review has stimulated so much interest from the intensive care community. However, it is a cause
for concern that four years following the publication of our review, in which we concluded that there is no evidence that albumin
administration reduced mortality in critically ill patients and a suggestion that it may increase mortality, that albumin continues to be
used and promoted. Hopefully, the SAFE trial (www.safestudy.net) will provide the evidence needed to resolve this issue.
Contributors
Comment: Dr PJ Horsey
Reply: Professor Ian Roberts
WH A T ’ S N E W
Last assessed as up-to-date: 2 August 2011.
Date Event Description
29 July 2011 New citation required but conclusions have not
changed
One new trial has been included, and the text has been
amended accordingly. The conclusions remain the same
The editorial group is aware that a clinical trial by Prof.
Joachim Boldt has been found to have been fabricated
(Boldt 2009). As the editors who revealed this fabrica-
tion point out (Reinhart 2011; Shafer 2011), this casts
some doubt on the veracity of other studies by the same
author. One trial by Prof. Boldt is included in this re-
view (Boldt 1993), but there were no deaths in the trial
and so the data do not contribute to the results. The
inclusion of the trial has no impact on the conclusions
of the review
The authors of the review have changed.
14 October 2008 New search has been performed Five new trials have been included in the review, and
the analysis, results and discussion sections have been
amended accordingly
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H I S T O R Y
Protocol first published: Issue 3, 1998
Review first published: Issue 3, 1998
Date Event Description
9 June 2008 Amended Converted to new review format.
20 August 2004 New citation required and conclusions have changed August 2004.
One new trial has been included (SAFE 2004)with the
analysis, results and discussion amended accordingly
6 February 2002 New search has been performed February 2002.
An updated search for new trials was done in Septem-
ber 2002. One trial was found meeting the inclusion
criteria but did not record data on mortality (Ernest
2001). Since the review was first published several new
randomised control trials have been initiated. Details
of these trials are given in the ongoing trials section
19 November 1999 Feedback has been incorporated Feedback added.
Response to feedback added.
C O N T R I B U T I O N S O F A U T H O R S
For the original version of the review; Phil Alderson (UK Cochrane Centre) searched The Cochrane Central Register of Controlled
Trials for relevant trials, extracted the data from the trials, and commented on the paper; Frances Bunn (London School of Hygiene
& Tropical Medicine) searched the Cochrane Injuries Group Specialised Register for relevant trials, obtained copies of relevant papers,
wrote to authors for further information on allocation concealment, and commented on the paper; Carol Lefebvre (UK Cochrane
Centre) designed the original search strategies for The Cochrane Central Register of Controlled Trials and EMBASE, and searched
these two databases for relevant trials; Leah Li (Institute of Child Health) did the funnel plot and the regression test of funnel plot
asymmetry; Alain Li Wan Po (Centre for Evidence-Based Pharmacotherapy, University of Nottingham) helped to write the paper; Ian
Roberts (London School of Hygiene & Tropical Medicine) designed the protocol, extracted data from the trials, contacted authors
for unpublished data, and wrote the paper; Gillian Schierhout proposed the study hypothesis, and conducted preliminary searches of
MEDLINE, EMBASE, and BIDS Index to Scientific and Technical Proceedings. For the 2008 update, Mia Pearson and Ian Roberts
screened the search results, extracted data from the trials and updated the analysis, results and discussion sections of the review. For the
2011 update, Karen Blackhall updated the search for studies. Ian Roberts extracted data from the additional trial (Maitland 2011) and
updated the analysis with Karen Blackhall.
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D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• Institute of Child Health, University College London, UK.
External sources
• NHS Research and Development, UK.
N O T E S
Please note that this review was also published in the BMJ 1998;317:235-40 (CIGAR 1998).
August 2011:
The editorial group is aware that a clinical trial by Prof. Joachim Boldt has been found to have been fabricated (Boldt 2009). As the
editors who revealed this fabrication point out (Reinhart 2011; Shafer 2011), this casts some doubt on the veracity of other studies by
the same author. One trial by Prof. Boldt is included in this review (Boldt 1993), but there were no deaths in the trial and so the data
do not contribute to the results. The inclusion of the trial has no impact on the conclusions of the review.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Blood Volume; Burns [blood; mortality; ∗therapy]; Cause of Death; Critical Illness [mortality; therapy]; Hypoproteinemia [blood;
mortality; ∗therapy]; Hypovolemia [blood; mortality; ∗therapy]; Plasma Substitutes [∗administration & dosage; adverse effects]; Ran-
domized Controlled Trials as Topic; Serum Albumin [∗administration & dosage; adverse effects]
MeSH check words
Humans
42Human albumin solution for resuscitation and volume expansion in critically ill patients (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
